SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (233)4/2/2001 12:07:10 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 539
 
``Our high affinity human antibodies married to proteomics technology are an ideal partnership,'' said Lisa. N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Yeah, as long as somebody else is doing the work and spending the money.

Remind me to take another look at Glaucus in the future.

Twenty five years or so ought to do.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News